JP2015502958A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502958A5
JP2015502958A5 JP2014546103A JP2014546103A JP2015502958A5 JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5 JP 2014546103 A JP2014546103 A JP 2014546103A JP 2014546103 A JP2014546103 A JP 2014546103A JP 2015502958 A5 JP2015502958 A5 JP 2015502958A5
Authority
JP
Japan
Prior art keywords
subject
effective amount
therapeutically effective
pathway inhibitor
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014546103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502958A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/068351 external-priority patent/WO2013086260A2/en
Publication of JP2015502958A publication Critical patent/JP2015502958A/ja
Publication of JP2015502958A5 publication Critical patent/JP2015502958A5/ja
Pending legal-status Critical Current

Links

JP2014546103A 2011-12-09 2012-12-07 がんの処置のための併用療法 Pending JP2015502958A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161568844P 2011-12-09 2011-12-09
US61/568,844 2011-12-09
US201261698030P 2012-09-07 2012-09-07
US61/698,030 2012-09-07
PCT/US2012/068351 WO2013086260A2 (en) 2011-12-09 2012-12-07 Combination therapy for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2015502958A JP2015502958A (ja) 2015-01-29
JP2015502958A5 true JP2015502958A5 (enExample) 2016-02-04

Family

ID=48575059

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014546103A Pending JP2015502958A (ja) 2011-12-09 2012-12-07 がんの処置のための併用療法

Country Status (4)

Country Link
US (1) US20150132301A1 (enExample)
EP (1) EP2788378A4 (enExample)
JP (1) JP2015502958A (enExample)
WO (1) WO2013086260A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2720721B1 (en) 2011-06-17 2017-08-30 President and Fellows of Harvard College Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
WO2015009851A1 (en) * 2013-07-16 2015-01-22 Icahn School Of Medicine At Mount Sinai Methods of treating cancer in subjects afflicted with metabolic dysfunction
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
EP3077546A4 (en) * 2013-12-02 2017-04-26 Oncomed Pharmaceuticals, Inc. Identification of predictive biomarkers associated with wnt pathway inhibitors
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP2975047A1 (en) * 2014-07-18 2016-01-20 Université de Lausanne Wnt7a polypeptides and their use
WO2017040666A2 (en) * 2015-08-31 2017-03-09 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US20200033346A1 (en) * 2017-03-16 2020-01-30 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic and therapeutic methods for kras positive cancers
CN107441045B (zh) * 2017-07-21 2018-10-19 广州源生医药科技有限公司 用于递送Wnt信号通路抑制剂的脂质体制剂及其制备方法
CA3175127A1 (en) 2020-03-12 2021-09-16 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378478A4 (en) * 2021-07-27 2025-11-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
WO2023114915A2 (en) * 2021-12-16 2023-06-22 D2G Oncology, Inc. Biomarkers for predicting responsiveness to mek inhibitor monotherapy and combination therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142481A0 (en) * 2001-04-05 2002-03-10 Yissum Res Dev Co A method for identifying consitutively active mutants of mitogen activated protein kinases (mapk) and uses thereof
EP1982718A4 (en) * 2006-02-09 2010-05-12 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF CANCER
EP2074226A2 (en) * 2006-09-19 2009-07-01 Novartis AG Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
JP5363350B2 (ja) * 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
JP5592253B2 (ja) * 2007-05-11 2014-09-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 過剰増殖性疾患およびマイトジェン細胞外キナーゼ活性関連性疾患を治療するための置換フェニルアミノ−ベンゼン誘導体
EP2164850B1 (en) * 2007-06-12 2016-01-13 Genentech, Inc. N-substituted azaindoles and methods of use
CN101801966A (zh) * 2007-07-18 2010-08-11 诺瓦提斯公司 双环杂芳基化合物和它们作为激酶抑制剂的用途
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
CN103479604B (zh) * 2007-07-30 2016-08-10 阿迪生物科学公司 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法
AU2008324203A1 (en) * 2007-11-05 2009-05-14 Novartis Ag Methods and compositions for measuring Wnt activation and for treating Wnt-related cancers
US8022057B2 (en) * 2007-11-12 2011-09-20 Takeda Pharmaceutical Company Limited MAPK/ERK kinase inhibitors
EP2331136B1 (en) * 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
MA33091B1 (fr) * 2009-03-11 2012-03-01 Ardea Biosciences Inc Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
TWI535445B (zh) * 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
EP2545187B1 (en) * 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN102971337B (zh) * 2010-04-01 2016-09-21 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
PE20141360A1 (es) * 2011-02-07 2014-10-13 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos.

Similar Documents

Publication Publication Date Title
IL267609B (en) Beta protein inhibitors in combination with Janus kinase inhibitors for the treatment of proliferative diseases
HUE036583T2 (hu) Notch jelzõ folyamat inhibitorai és alkalmazásuk rákok kezelésében
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
BR112014009755A2 (pt) tratamento de câncer com inibidores de quinase tor
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
PL3489261T3 (pl) Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
IL243976B (en) kdm1a inhibitors for disease treatment
WO2015003360A3 (en) Therapeutically active compounds and their methods of use
HK1216175A1 (zh) 治療性化合物和組合物
EP3065549A4 (en) Methods for inhibiting tie2 kinase useful in the treatment of cancer
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
IL234640B (en) Cancer treatment with rapamycin target site kinase inhibitors
HRP20181462T1 (hr) Kombinacija regorafeniba i acetilsalicilne kiseline za liječenje raka debelog crijeva
HUE068364T2 (hu) Faktor 1 fehérje betegségek kézélésében vagy megelõzésében váló alkalmazásra
PL3004108T3 (pl) Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób
ZA201406708B (en) Treatment of cancer with tor kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
ZA201607740B (en) Treatment of the complications of chronic liver disease with caspase inhibitors
PL3456333T3 (pl) Zastosowanie inhibitora telomerazy imetelstatu do leczenia zespołu mielodysplastycznego
IL234641B (en) Cancer treatment with rapamycin target site kinase inhibitors
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
HK1223924A1 (zh) 治疗活性化合物及其使用方法
JP2013231052A5 (enExample)
PL2831110T3 (pl) Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych